Retinal diseases, such as diabetic retinopathy and age-related macular degeneration, can lead to irreversible blindness if not treated promptly. Current treatment options may not always be effective in preventing or reversing vision loss caused by these conditions.

Osanni Bio is a biotechnology company focused on developing innovative therapies to prevent and reverse blindness resulting from retinal diseases. The company employs a design thinking approach in its drug development process, specifically targeting ocular diseases to enable physicians to effectively preserve patients' eyesight. Their therapeutic strategies aim to address the underlying causes of retinal degeneration, offering potential solutions for patients at risk of vision loss. By focusing on novel mechanisms and delivery methods, Osanni Bio strives to improve outcomes for individuals affected by debilitating eye conditions.

Development of targeted therapies for retinal diseases

Focus on preventing and reversing blindness

Utilization of a design thinking approach in drug development

The primary target audience includes ophthalmologists and other physicians treating patients with retinal diseases, as well as patients at risk of vision loss due to these conditions.